Mechanisms of protein degradation in Trypanosoma cruzi.
Proteolysis of endogenous proteins may play a key role in the adaptation of T. cruzi to the different host environments to which it is exposed during its complex life cycle. For this reason, we have attempted to study the intracellular pathways of protein degradation in the non infective epimastigotes form (EP strain) of T. cruzi. Following intracellular proteolysis by pulse chase experiments with 35 S methionine, we observed a significant inhibition (50%) of the degradation of endogenous proteins in log phase parasites in the presence of inhibitors of lysosomal functions, such as chloroquine and E 64. A significant increase in proteolysis was observed in stationary phase parasites which was reverted to log phase values by supplementing the chase medium with 0.5% glucose or 10% serum, or in the presence of chloroquine. Under this condition of nutritional stress, we could observe an increase in the activity of acid proteases. A significant increase in the degradation rates was observed when abnormal proteins were induced in the parasite by amino acid analogs and puromycin. This increase was not affected by E 64, suggesting the participation of non lysosomal mechanisms in the degradation of rapidly degradable abnormal proteins. Under these conditions, we could observe an increase in high molecular weight conjugates of ubiquitin with respect to endogenous proteins. These results suggest the importance of lysosomal mechanisms in the degradation of cellular proteins in nutritional optimal conditions and during nutritional deprivation, and the possible involvement of the ubiquitin system in the degradation of high turnover proteins.
Henriquez
D A
DA
Departamento de Biología Celular, Universidad Simón Bolívar, Caracas, Venezuela.
Perez
N
N
Pance
A
A
Bradley
C
C
D000818:Animals; D002738:Chloroquine / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007425:Intracellular Membranes / Q000378:metabolism; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D008970:Molecular Weight; D010447:Peptide Hydrolases / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology; D015800:Protozoan Proteins / Q000378:metabolism*; D011691:Puromycin / Q000494:pharmacology; D013997:Time Factors; D014349:Trypanosoma cruzi / Q000201:enzymology / Q000254:growth & development / Q000378:metabolism*; D014452:Ubiquitins / Q000378:metabolism
D011480:Protease Inhibitors; D015800:Protozoan Proteins; D014452:Ubiquitins; D011691:Puromycin; D002738:Chloroquine; D010447:Peptide Hydrolases; D003546:Cysteine Endopeptidases; D007930:Leucine; C024974:E 64